Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Tax Provisions (2020 - 2022)

Tarsus Pharmaceuticals (TARS) has 3 years of Tax Provisions data on record, last reported at -$5000.0 in Q3 2022.

  • For Q3 2022, Tax Provisions rose 98.53% year-over-year to -$5000.0; the TTM value through Jun 2023 reached -$5000.0, up 98.25%, while the annual FY2025 figure was $2.1 million, N/A changed from the prior year.
  • Tax Provisions reached -$5000.0 in Q3 2022 per TARS's latest filing, down from $1000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $313000.0 in Q1 2021 and bottomed at -$341000.0 in Q3 2021.
  • Average Tax Provisions over 3 years is $7428.6, with a median of $1000.0 recorded in 2020.
  • Peak YoY movement for Tax Provisions: plummeted 34200.0% in 2021, then surged 98.53% in 2022.
  • A 3-year view of Tax Provisions shows it stood at $1000.0 in 2020, then surged by 5300.0% to $54000.0 in 2021, then tumbled by 109.26% to -$5000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$5000.0 in Q3 2022, $1000.0 in Q1 2022, and $54000.0 in Q4 2021.